Acadian Asset Management LLC lifted its holdings in Recro Pharma Inc (NASDAQ:REPH) by 376.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 224,062 shares of the specialty pharmaceutical company’s stock after acquiring an additional 177,013 shares during the period. Acadian Asset Management LLC owned 1.09% of Recro Pharma worth $1,125,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Jump Trading LLC purchased a new stake in shares of Recro Pharma in the first quarter worth approximately $124,000. Citadel Advisors LLC purchased a new stake in shares of Recro Pharma in the first quarter worth approximately $126,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Recro Pharma in the first quarter worth approximately $139,000. Two Sigma Investments LP purchased a new stake in shares of Recro Pharma in the fourth quarter worth approximately $164,000. Finally, Deutsche Bank AG raised its holdings in shares of Recro Pharma by 141.6% in the fourth quarter. Deutsche Bank AG now owns 30,446 shares of the specialty pharmaceutical company’s stock worth $281,000 after buying an additional 17,845 shares during the period. 55.86% of the stock is owned by hedge funds and other institutional investors.
Several brokerages recently issued reports on REPH. ValuEngine raised Recro Pharma from a “sell” rating to a “hold” rating in a research note on Thursday, June 28th. Janney Montgomery Scott dropped their price objective on Recro Pharma from $21.00 to $11.00 and set a “fair value” rating on the stock in a research note on Thursday, May 24th. Oppenheimer set a $18.00 price objective on Recro Pharma and gave the stock a “buy” rating in a research note on Wednesday, August 8th. Zacks Investment Research cut Recro Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, May 15th. Finally, Piper Jaffray Companies dropped their target price on Recro Pharma from $17.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, May 24th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $12.63.
Recro Pharma (NASDAQ:REPH) last issued its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.34) by $0.72. The company had revenue of $21.74 million during the quarter, compared to analyst estimates of $16.81 million. Recro Pharma had a negative return on equity of 144.84% and a negative net margin of 75.19%. equities research analysts anticipate that Recro Pharma Inc will post -2.5 earnings per share for the current fiscal year.
Recro Pharma Profile
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Read More: Trading Penny Stocks
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.